Coronary Artery Bypass Graft Market (2025 - 2033) Size, Share & Trends Analysis Report By Method (On-pump, Off-pump), By Surgical Procedure (Single CABG Surgery, Double CABG Surgery), By End-use, By Region, And Segment Forecasts

Coronary Artery Bypass Graft Market Summary

The global coronary artery bypass graft market size was estimated at USD 19.24 billion in 2024 and is projected to reach USD 27.66 billion by 2033, growing at a CAGR of 3.86% from 2025 to 2033. Increasing the prevalence of cardiovascular disease is one of the key aspects driving market growth.

According to an Oxford Academic article published in January 2025, the global burden of cardiovascular disease remains substantial, with an age-standardized prevalence of approximately 7,179 cases per 100,000 individuals. This high prevalence underlines the growing need for effective treatment options, particularly for coronary artery disease, which is a leading contributor to cardiovascular-related morbidity and mortality. 

The increasing incidence of CAD drives market growth. According to the CDC article published in October 2024, in the U.S., coronary artery disease (CAD) affects a significant portion of the population, with nearly 1 in 20 adults aged 20 years and older, approximately 5% living with the condition. This sizable patient pool highlights the ongoing clinical challenge posed by CAD, which remains a leading cause of heart-related morbidity and mortality. For many individuals, advanced cases of CAD require surgical intervention when less invasive treatments prove insufficient. As a result, coronary artery bypass grafting (CABG) continues to serve as a vital therapeutic approach, reinforcing its importance within the broader cardiovascular treatment landscape and underscoring its role as a key driver of market demand.

Table 1: CVD incidence in the U.S., 2024

Source:  Endocrine Society, News-Medical.net  & GVR

Advancements in graft technology are paving the way for more effective and durable solutions in CABG procedures. For instance, in July 2025, Xeltis, a transformative implant developer, introduced Xabg, a synthetic coronary artery bypass conduit (CABG). This innovative graft is designed to enable the natural creation of living and long-lasting vessels. Preliminary clinical data from an EU clinical trial have demonstrated positive safety and patency outcomes among patients with multi-vessel atherosclerotic coronary artery disease. Xabg represents a significant advancement in graft technology, aiming to address the limitations of traditional grafts by promoting endothelial cell growth and integration with the patient's vascular system.

Moreover, integrating robotics into CABG procedures transforms surgical approaches, offering enhanced precision and reduced invasiveness. According to OAE Publishing Inc., an article published in August 2025, Robotic-assisted CABG has emerged as a minimally invasive alternative to traditional open-heart surgery, offering reduced surgical trauma and faster recovery. Techniques include robotic-assisted minimally invasive direct coronary artery bypass (RA-MIDCAB), where the internal thoracic artery is harvested robotically and anastomosed via mini-thoracotomy, and totally endoscopic CABG (TECAB), which avoids thoracotomy altogether. These advancements reshape operative planning and execution, enhancing precision and reducing invasiveness in coronary revascularization procedures.

The landscape of CABG reimbursement in the U.S. is evolving rapidly, reflecting the healthcare industry’s push toward value-based care. A significant trend is the introduction of bundled payment models that streamline reimbursement and incentivize quality. According to the American College of Cardiology Foundation in April 2024, the Centers for Medicare & Medicaid Services (CMS) proposed the Transforming Episode Accountability Model (TEAM), a mandatory hospital episode-based payment model set to start in January 2026. This model bundles payments for CABG surgeries and other high-cost procedures, ensuring more predictable reimbursement and encouraging hospitals to optimize care pathways for improved patient outcomes.

Parallel to bundled payments, physician fee schedule updates have shaped reimbursement trends. According to an Atricure article, effective January 1, 2025, the Medicare Physician Fee Schedule (PFS) revised reimbursement rates for CABG procedures, including the single arterial graft CABG (CPT code 33533) at approximately USD 1,789. These adjustments ensure payments align with current clinical practice and operational costs, reinforcing fair compensation for hospitals and surgeons performing complex cardiac procedures.

Table 2: Key Reimbursement Policies Impacting CABG Market

Moreover, expanding coverage for minimally invasive CABG techniques reflects increasing acceptance of advanced surgical approaches. As of January 2025, Blue Cross Blue Shield of Rhode Island updated its medical policy to cover Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery. The policy recognizes the benefits of less invasive procedures, such as reduced recovery times and enhanced patient outcomes. However, other minimally invasive approaches, such as Port Access CABG (PACAB) and Total Endoscopic CABG (TECAB), remain excluded due to limited evidence of improved outcomes.

Market Concentration & Characteristics

The market experienced notable innovations, including ongoing innovations focusing on minimizing invasiveness through techniques like robotics and advanced imaging. Advancements in stent technology, biodegradability, and personalized medicine contribute to improving patient outcomes.

Market players, such as Medtronic plc, Novadaq Technologies Inc., and Terumo Corporation, are involved in mergers and acquisitions. These activities allow key market players to extend their geographical footprint and venture into new regions.

Stringent regulatory requirements in the CABG market ensure the safety and efficacy of procedures and devices, influencing product development timelines and market access.

Emerging alternatives such as drug-eluting stents and catheter-based interventions pose potential substitutes for traditional CABG procedures, offering less invasive options for managing coronary artery disease.

Companies in the coronary artery bypass graft industry are pursuing regional expansion strategies, targeting markets with a high prevalence of cardiovascular diseases and collaborating with local healthcare providers to broaden their geographic footprint.

Method Insights

By method, the on-pump segment dominated the market in 2024 and accounted for the largest revenue share of 66.80%. The on-pump (cardiopulmonary bypass-assisted) method is a primary approach of surgical revascularization, particularly for complex and multivessel disease. The segment's growth is driven by advancements in perfusion systems, integrated monitoring tools, and hybrid minimally invasive approaches. These innovations enhance safety, precision, and patient outcomes under extracorporeal support, reinforcing the preference for on-pump surgery in challenging anatomical scenarios. For instance, in March 2023, LivaNova Essenz Perfusion System combines a next-generation heart-lung machine (HLM) with an integrated patient monitor for real-time data feedback. LivaNova secured U.S. FDA 510(k) clearance for the Essenz system, enabling more tailored perfusion strategies based on patient physiology and potentially reducing complications of bypass support.

The off-pump segment in the market is anticipated to witness the fastest CAGR over the forecast period. It serves patients at higher risk from cardiopulmonary bypass while concurrently driving innovations to expand its applicability. The segment is experiencing growth primarily driven by the shift toward minimally invasive, robotic, and endoscopic-assisted techniques. These advances are helping preserve the inherent advantages of off-pump surgery, such as reduced systemic inflammation, lower risk of stroke, less bleeding, and shorter ICU stays, while addressing earlier limitations such as incomplete revascularization and technical challenges in multivessel grafting. With these technological improvements, the off-pump segment is becoming more attractive to surgeons and patients, supporting its expansion in the broader CABG market.

Surgical Procedure Insights

Triple CABG surgery dominated the market in 2024 and accounted for the largest revenue share of 41.76%. Triple CABG is a surgical procedure performed to bypass blockages in all three major coronary arteries left anterior descending (LAD), left circumflex (LCx), and right coronary artery (RCA), to restore adequate blood flow to the heart muscle. This procedure is typically recommended for patients with severe triple-vessel coronary artery disease, where less invasive treatments may be insufficient. According to the American College of Cardiology Foundation article published in March 2025, the FAME-3 trial compared outcomes of patients with triple-vessel disease undergoing CABG versus percutaneous coronary intervention (PCI). The trial, which included 1,500 patients from North America, Europe, Asia, and Australia, found that after five years, there were no significant differences between the two groups in the primary composite endpoint of death, stroke, or heart attack.

The single CABG surgery segment in the market is anticipated to witness the fastest CAGR over the forecast period. Single coronary artery bypass grafting (CABG) is a surgical procedure to restore blood flow to a single blocked coronary artery, most commonly the left anterior descending artery, using a graft, usually from the internal thoracic artery. This procedure suits patients with isolated lesions, providing targeted revascularization with reduced invasiveness and faster recovery than multi-vessel CABG. The current trend in this segment emphasizes minimally invasive approaches, including robotic-assisted and off-pump techniques, which aim to preserve graft patency, reduce trauma, and enhance long-term survival. According to an NCBI article published in April 2025, a recent instance demonstrating the efficacy of minimally invasive single CABG is from a long-term study evaluating conventional CABG versus minimally invasive direct coronary artery bypass (MIDCAB). Out of 1,915 patients treated, 163 underwent MIDCAB using a single internal thoracic artery graft. The study revealed early mortality of only 0.6% in the MIDCAB group compared to 3.6% for conventional CABG.

End-use Insights

The hospital segment dominated the market in 2024 with a revenue share of 50.74%. Hospitals remain the primary setting for CABG procedures in the U.S. because they possess the surgical infrastructure, specialized staff, and intensive care capabilities needed to manage complex cardiac patients. Nationally, outcomes and procedural volumes are increasingly scrutinized through benchmarking systems such as those maintained by the Centers for Medicare & Medicaid Services (CMS) and the Society of Thoracic Surgeons (STS). This trend has increased hospital reporting transparency, where survival rates, complication profiles, and 30-day outcomes are publicly available.

The cardiology centers segment of the market is anticipated to register the fastest growth rate over the forecast period. Cardiology centers across the U.S. are at the forefront of advancing Coronary Artery Bypass Graft (CABG) procedures, incorporating innovative techniques and technologies to enhance patient outcomes. These centers are increasingly adopting minimally invasive and robotic-assisted surgeries, reflecting a significant shift towards less invasive, more precise interventions. For instance, in April 2025, John Muir Health’s Concord Medical Center emerged as a leading institution in coronary artery bypass graft (CABG) surgery, demonstrating remarkable patient outcomes. In recent evaluations, the center achieved an impressive 30-day survival rate of 98.45% for patients undergoing CABG procedures. This exceptional performance positions the hospital as the top-ranking facility in California for heart bypass surgery, placing it among the top ten centers nationally.

Regional Insights

North America dominated the coronary artery bypass graft market in 2024 and accounted for the largest revenue share of 50.74% owing to a well-established healthcare infrastructure and high healthcare expenditure. Moreover, technologically advanced product launches drive the growth of the market. For instance, in October 2023, Marizyme, Inc. received FDA De Novo clearance for DuraGraft, its first-in-class vascular conduit preservation solution. The product is approved for adult CABG surgeries, specifically for flushing and storing saphenous vein grafts. Reducing oxidative damage, DuraGraft helps maintain grafts' structural and functional integrity. Clinical evidence, including imaging studies, shows that DuraGraft reduces graft wall thickening at 12 months and is linked to lower long-term mortality up to three years after CABG. 

U.S. Coronary Artery Bypass Graft Market Trends

The coronary artery bypass graft market in the U.S. held the largest share, 92.72%, in 2024. Rising CVD cases in the U.S. drive market growth. According to the CDC article published in October 2024, in the U.S., cardiovascular disease remains a critical public health concern, claiming a life approximately every 34 seconds. This alarming mortality rate underscores the ongoing burden of heart disease, particularly coronary artery disease (CAD), which is a leading indication for CABG procedures. The high prevalence of CAD translates into substantial demand for CABG surgeries, as these interventions are essential for restoring blood flow to the heart and improving patient survival.

Canada coronary artery bypass graft market is anticipated to register the fastest growth rate during the forecast period. Increasing CVD incidence drives market growth. According to a Government of Canada article published in October 2024, CVDs represent a major public health challenge in Canada, ranking as the second leading cause of death after cancer. Currently, around 2.4 million Canadians are living with heart disease, which contributes significantly to the country's overall burden of disease and is the leading cause of years of life lost.

Europe Coronary Artery Bypass Graft Market Trends

The coronary artery bypass graft market in Europe is anticipated to register a significant growth rate during the forecast period. The growth is driven by the increasing incidence of CVD and CAD and technologically advanced product launches and approvals. For instance, in July 2025, Xabg, from the Dutch company Xeltis, is a novel polymeric, biorestorative conduit designed for CABG. The conduit is based on their Endogenous Tissue Restoration (ETR) platform, aiming to be replaced by living tissue over time. A clinical trial in the EU has delivered preliminary data showing positive safety and patency in patients with multi-vessel coronary artery disease. The Xabg conduit remained open and functional in a different patient, with excellent flow at 24 months. This is notable because off-the-shelf small-diameter vascular grafts with prolonged, durable patency are rare.

Germany coronary artery bypass graft market is anticipated to grow considerably during the forecast period. Increasing CHD cases drive market growth. According to the NCBI article published in June 2025, CHD remains a leading health concern in Germany, significantly influencing the demand for surgical interventions such as coronary artery bypass grafting (CABG). In 2023, CHD accounted for approximately 119,800 deaths, underscoring the widespread impact of this condition on the population. The high prevalence of CHD highlights the ongoing need for effective revascularization procedures, positioning CABG as a critical treatment option for patients with advanced coronary artery disease.

The coronary artery bypass graft market in Italy is anticipated to grow considerably during the forecast period. The increasing incidence of CVD in Italy is driving the demand for Italian coronary artery bypass grafts. According to the Italian Federation of Cardiology article published in 2024, cardiovascular disease remains the primary cause of death in Italy, responsible for approximately 44% of total fatalities, a figure that surpasses the European average. With an estimated prevalence of 7,499 cases per 100,000 individuals, the country faces a substantial burden of disease, primarily driven by its rapidly aging population, which is among the oldest in Europe. This rising incidence of cardiovascular conditions underlines the increasing demand for advanced treatment options such as coronary artery bypass graft (CABG) procedures. 

Spain coronary artery bypass graft market is anticipated to register a significant growth rate during the forecast period. Increasing CVD incidence drives market growth. According to a Revista Española de Cardiología article published in March 2025, CVD remains a significant health concern in Spain. However, its mortality rates are relatively lower compared to neighboring European countries. In 2023, the CVD-related death rate was 255 per 100,000 population among men and 176 per 100,000 among women.

Asia Pacific Coronary Artery Bypass Graft Market Trends

The coronary artery bypass graft market in the Asia Pacific is anticipated to be the fastest-growing region, driven by advancements in surgical techniques, increasing healthcare accessibility, and a growing emphasis on minimally invasive procedures. For instance, in June 2025, in India, Sir Sunderlal Hospital at Banaras Hindu University in Varanasi recently performed a pioneering total arterial bypass grafting surgery, utilizing exclusively arterial grafts from both sides of the chest and the non-dominant hand. This approach offers long-term benefits, with arterial grafts having a lifespan exceeding 20 years, compared to the typical 10-year duration of venous grafts. The success of this procedure marks a significant milestone in cardiac care in Eastern Uttar Pradesh and showcases the region's commitment to adopting advanced surgical techniques.

Japan coronary artery bypass graft market is anticipated to register a significant growth rate during the forecast period. The growing adoption of minimally invasive CABG techniques in Japan, which reflects both technological advancement and an emphasis on improving postoperative recovery and patient outcomes, drives market growth. According to an article published in the International Society for Minimally Invasive Cardiothoracic Surgery in June 2024, in Japan, a recent study conducted at Hakodate Goryoukaku Hospital evaluated the safety and effectiveness of aorta no-touch total arterial minimally invasive coronary artery bypass grafting (MICS CABG) compared with the traditional off-pump coronary artery bypass (OPCAB) using sternotomy. The study involved 100 patients, equally divided between MICS CABG and OPCAB groups, matched for age, gender, left ventricular function, and number of diseased vessels.

The coronary artery bypass graft market in China is anticipated to register a significant growth rate during the forecast period. Increasing CVD and CAD incidence drives market growth. According to the Beijing Renhe Information Technology Co. Ltd article published in August 2025, CVD poses a significant health challenge in China, affecting approximately 330 million people across the country. Among these, around 13 million individuals suffer from stroke, while 11.39 million are diagnosed with coronary heart disease (CHD). This substantial prevalence underscores the growing demand for advanced interventions such as CABG to manage complex coronary conditions. 

India coronary artery bypass graft market is anticipated to register a significant growth rate during the forecast period. The increasing CVD burden in India is driving the market's growth. According to the Economic Times article published in February 2024, the study reveals that India faces a significant cardiovascular disease (CVD) burden, with an age-standardized CVD death rate of 272 per 100,000 population. This rate surpasses the global average of 235 per 100,000 population, indicating a higher prevalence of CVD in India. This elevated burden emphasizes the urgent need for advanced coronary artery bypass graft management solutions to address the growing challenges in cardiovascular health nationwide.

Latin America Coronary Artery Bypass Graft Market Trends

The coronary artery bypass graft market in Latin America is growing over the forecast period, fueled by rising cardiovascular disease prevalence linked to lifestyle factors such as obesity, hypertension, and diabetes. The region is witnessing ongoing investments in healthcare infrastructure, particularly in public and private hospitals, expanding their cardiac surgery capacities. Despite persistent economic and healthcare disparities between urban and rural areas, government initiatives and cardiovascular disease awareness programs increase access to CABG procedures.

Brazil coronary artery bypass graft market is expected to grow over the forecast period. Increasing CVD incidence drives market growth. According to the Elsevier Ltd. article published in July 2025, in Brazil, cardiovascular diseases (CVDs) remain a leading public health concern, accounting for approximately 30% of all deaths. Over recent decades, CVDs have consistently been the primary cause of mortality, surpassed only by COVID-19 during the pandemic years of 2020 and 2021. This persistent high prevalence of heart disease has directly influenced the demand for surgical interventions such as coronary artery bypass grafting (CABG), as patients increasingly present with advanced coronary artery disease.

Middle East & Africa Coronary Artery Bypass Graft Market Trends

The coronary artery bypass graft market in the MEA is growing over the forecast period, driven by the growing prevalence of cardiovascular diseases, including coronary artery disease, a leading cause of mortality in the region. The market is also driven by increasing heart health awareness, rising healthcare expenditures, and adopting advanced surgical technologies such as minimally invasive and robotic-assisted CABG procedures. Key players in the region include global medical device manufacturers that supply graft materials, surgical instruments, and cardiopulmonary bypass systems, alongside local hospitals and cardiac centers that implement these technologies.

South Africa coronary artery bypass graft marketis growing over the forecast period. Increasing CVD incidence in South Africa drives market growth. According to an NCBI article published in May 2024, CVDs represent a significant public health challenge in South Africa, accounting for approximately 17.3% of all deaths, or nearly one in six fatalities. This high mortality underscores the urgent need for effective interventions to manage coronary artery disease (CAD) and other heart conditions. As a result, there is a growing demand for CABG procedures within the country, particularly in tertiary care hospitals and specialized cardiac centers.

Key Coronary Artery Bypass Graft Company Insights

Key market participants focus on devising innovative business growth strategies for product portfolio expansions, partnerships and collaborations, mergers and acquisitions, and business footprint expansions.

Recent Developments

• In June 2025, Medtronic announced a strategic collaboration with IRCAD North America to advance surgical training and innovation. The partnership will have Medtronic medical-education teams co-developing hands-on courses at IRCAD North America that feature Medtronic products and techniques for cardiovascular and minimally invasive surgery, supporting wider adoption of advanced revascularization procedures.

• In December 2024, Terumo Health Outcomes and Medis Medical Imaging entered a strategic partnership to enhance cardiovascular care in the U.S. The collaboration combines Terumo’s ePRISM precision medicine software platform with Medis’ QFR technology to improve diagnostic accuracy and treatment planning for coronary artery disease.

• In August 2024, Transonic Systems Inc. entered an exclusive global distribution partnership with ADInstruments, ensuring the supply of volume flow products for life science research. This collaboration aims to provide stability and support to researchers in biomedical and cardiovascular studies.

Coronary Artery Bypass Graft Market Report Scope

Global Coronary Artery Bypass Graft Market Report Segmentation

This report forecasts revenue and volume growth at global, regional, and country levels and analyzes industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global coronary artery bypass graft market report based on method, surgical procedure, end-use, and region:

• Method Outlook (Revenue USD Million, 2021 - 2033)

  • Off-pump

  • On-pump

  • Minimally Invasive Direct CABG (MIDCAB)

• Surgical Procedure Outlook (Revenue USD Million, 2021 - 2033) (Procedure Volume, In Thousand, 2021 - 2033)

  • Single CABG Surgery

  • Double CABG Surgery

  • Triple CABG Surgery

  • Quadruple CABG Surgery

• End-use Outlook (Revenue USD Million, 2021 - 2033)

  • Hospitals

  • Cardiology Centers

  • Others

• Regional Outlook (Revenue USD Million, 2021 - 2033) (Procedure Volume, In Thousand, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • Spain

    • Italy

    • France

    • Denmark

    • Norway

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait